Kite Pharma Inc (NASDAQ:KITE) is the subject of a new 13G filing issued by Andreas Halvorsen‘s Viking Global. The filing shows that the billionaire Tiger Cub has buffed his stake in the company to 2.44 million shares, up from 2.21 million shares at the end of 2015, when Viking Global owned the second-largest position in the stock among investors in our database. The current position now amasses an even 5.0% of the company’s stock. The full content of the filing can be found below.
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Viking Global Investors | 0 | 2,441,232 | 0 | 2,441,232 | 2,441,232 | 5.0% |
Viking Global Performance | 0 | 1,648,367 | 0 | 1,648,367 | 1,648,367 | 3.4% |
Viking Global Equities | 0 | 562,091 | 0 | 562,091 | 562,091 | 1.2% |
Viking Global Equities II | 0 | 32,967 | 0 | 32,967 | 32,967 | 0.1% |
VGE III Portfolio Ltd | 0 | 1,053,309 | 0 | 1,053,309 | 1,053,309 | 2.2% |
Viking Long Fund GP | 0 | 616,489 | 0 | 616,489 | 616,489 | 1.3% |
Viking Long Fund Master Ltd | 0 | 616,489 | 0 | 616,489 | 616,489 | 1.3% |
Viking Global Opportunities GP | 0 | 176,376 | 0 | 176,376 | 176,376 | 0.4% |
Viking Global Opportunities Portfolio GP | 0 | 176,376 | 0 | 176,376 | 176,376 | 0.4% |
Viking Global Opportunities Liquid Portfolio Sub-Master | 0 | 176,376 | 0 | 176,376 | 176,376 | 0.4% |
O. Andreas Halvorsen | 0 | 2,441,232 | 0 | 2,441,232 | 2,441,232 | 5.0% |
David C. Ott | 0 | 2,441,232 | 0 | 2,441,232 | 2,441,232 | 5.0% |
Daniel S. Sundheim | 0 | 2,441,232 | 0 | 2,441,232 | 2,441,232 | 5.0% |
Follow Andreas Halvorsen's Viking Global
Page 1 of 20 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
Schedule 13G
________________
INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934*
Kite Pharma, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
49803L109
(CUSIP Number)
February 18, 2016
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
___________
* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 2 of 20 SEC Filing
Schedule 13G PAGE 2 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Investors LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
2,441,232
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
2,441,232
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,441,232
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.0%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 3 of 20 SEC Filing
Schedule 13G PAGE 3 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Performance LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
1,648,367
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
1,648,367
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,648,367
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
3.4%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 4 of 20 SEC Filing
Schedule 13G PAGE 4 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Equities LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
562,091
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
562,091
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
562,091
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.2%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 5 of 20 SEC Filing
Schedule 13G PAGE 5 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Equities II LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
32,967
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
32,967
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
32,967
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.1%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 6 of 20 SEC Filing
Schedule 13G PAGE 6 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
VGE III Portfolio Ltd.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
1,053,309
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
1,053,309
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
1,053,309
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
2.2%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
CO
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 7 of 20 SEC Filing
Schedule 13G PAGE 7 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Long Fund GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
616,489
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
616,489
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
616,489
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.3%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 8 of 20 SEC Filing
Schedule 13G PAGE 8 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Long Fund Master Ltd.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
616,489
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
616,489
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
616,489
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
1.3%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
CO
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 9 of 20 SEC Filing
Schedule 13G PAGE 9 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
176,376
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
176,376
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
176,376
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.4%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 10 of 20 SEC Filing
Schedule 13G PAGE 10 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities Portfolio GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
176,376
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
176,376
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
176,376
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.4%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 11 of 20 SEC Filing
Schedule 13G PAGE 11 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities Liquid Portfolio Sub-Master LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
176,376
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
176,376
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
176,376
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
0.4%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 12 of 20 SEC Filing
Schedule 13G PAGE 12 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
O. Andreas Halvorsen
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Norway
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
2,441,232
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
2,441,232
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,441,232
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.0%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 13 of 20 SEC Filing
Schedule 13G PAGE 13 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
David C. Ott
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
2,441,232
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
2,441,232
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,441,232
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.0%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 14 of 20 SEC Filing
Schedule 13G PAGE 14 of 20
CUSIP No. 49803L109
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Daniel S. Sundheim
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________
BENEFICIALLY (6) SHARED VOTING POWER
2,441,232
OWNED BY ______________________________________________________________
EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________
PERSON WITH (8) SHARED DISPOSITIVE POWER
2,441,232
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,441,232
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
5.0%
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 15 of 20 SEC Filing
Schedule 13G PAGE 15 of 20
CUSIP No. 49803L109
ITEM 1(a). NAME OF ISSUER:
Kite Pharma, Inc.
ITEM 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
2225 Colorado Avenue
Santa Monica, California 90404
ITEM 2(a). NAME OF PERSON FILING:
Viking Global Investors LP (“VGI”),
Viking Global Performance LLC (“VGP”),
Viking Global Equities LP (“VGE”),
Viking Global Equities II LP (“VGEII”),
VGE III Portfolio Ltd. (“VGEIII”),
Viking Long Fund GP LLC (“VLFGP”),
Viking Long Fund Master Ltd. (“VLFM”),
Viking Global Opportunities GP LLC (“Opportunities GP”),
Viking Global Opportunities Portfolio GP LLC
(“Opportunities Portfolio GP”),
Viking Global Opportunities Liquid Portfolio Sub-Master LP
(“Opportunities Fund”),
O. Andreas Halvorsen, David C. Ott and
Daniel S. Sundheim (collectively, the “Reporting Persons”)
ITEM 2(b). ADDRESS OF PRINCIPAL OFFICE OR, IF NONE, RESIDENCE:
The business address of each of the Reporting Persons is
55 Railroad Avenue, Greenwich, Connecticut 06830.
ITEM 2(c). CITIZENSHIP:
VGI, VGE and VGEII are Delaware limited partnerships;
VGEIII and VLFM are Cayman Islands exempted companies;
VGP, VLFGP, Opportunities GP and Opportunities Portfolio GP
are Delaware limited liability companies; and Opportunities Fund
is a Cayman Islands exempted limited partnership.
O. Andreas Halvorsen is a citizen of Norway.
David C. Ott and Daniel S. Sundheim are citizens of
the United States.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, par value $0.001 per share (“Common Stock”)
ITEM 2(e). CUSIP NUMBER: 49803L109
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c),
CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under Section 15 of the
Act
(b) [ ] Bank as defined in Section 3(a)(6) of the Act
(c) [ ] Insurance Company as defined in Section 3(a)(19) of
the Act
(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940
(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940: see Rule 13d-
1(b)(1)(ii)(E)
(f) [ ] Employee Benefit Plan, Pension Fund which is subject
to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see Rule 13d-
1(b)(1)(ii)(F)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 16 of 20 SEC Filing
Schedule 13G PAGE 16 of 20
CUSIP No. 49803L109
(g) [ ] Parent Holding Company, in accordance with Rule 13d-
1(b)(ii)(G)
(h) [ ] Savings Associations as defined in Section 3(b) of the
Federal Deposit Insurance Act
(i) [ ] Church Plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940
(j) [ ] A non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J)
(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J), please specify
the type of institution:
ITEM 4. OWNERSHIP.
A. VGI
(a) Amount beneficially owned: 2,441,232
(b) Percent of class: 5.0%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,441,232
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,441,232
VGI provides managerial services to VGE, VGEII, VGEIII, VLFM
and Opportunities Fund. VGI has the authority to dispose of and vote
the shares of Common Stock.
Based on Rule 13d-3 of the Securities Exchange Act of 1934,
as amended (the “Act”), VGI may be deemed to beneficially
own the shares of Common Stock directly held by VGE, VGEII,
VGEIII, VLFM and Opportunities Fund. VGI does not directly own
any shares of Common Stock.
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 17 of 20 SEC Filing
Schedule 13G PAGE 17 of 20
CUSIP No. 49803L109
B. VGP
(a) Amount beneficially owned: 1,648,367
(b) Percent of class: 3.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,648,367
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,648,367
VGP, as the general partner of VGE and VGEII, has the
authority to dispose of and vote the shares of Common Stock
directly owned by VGE and VGEII. VGP serves as investment
manager to VGEIII and has the authority to dispose of and vote
the shares of Common Stock directly owned by VGEIII. VGP does
not directly own any shares of Common Stock.
Based on Rule 13d-3 of the Act, VGP may be deemed to
beneficially own the shares of Common Stock directly held by
VGE, VGEII and VGEIII.
C. VLFGP
(a) Amount beneficially owned: 616,489
(b) Percent of class: 1.3%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
616,489
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 616,489
VLFGP serves as the investment manager of VLFM and has the
authority to dispose of and vote the shares of Common Stock
directly owned by VLFM. VLFGP does not directly own
any shares of Common Stock.
Based on Rule 13d-3 of the Act, VLFGP may be deemed to
beneficially own the shares of Common Stock directly held by
VLFM.
D. Opportunities GP
(a) Amount beneficially owned: 176,376
(b) Percent of class: 0.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
176,376
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 176,376
Opportunities GP serves as the sole member of Opportunities
Portfolio GP and has the authority to dispose of and vote the
shares of Common Stock controlled by Opportunities Portfolio GP,
which consists of the shares of Common Stock directly held by
Opportunities Fund. Opportunities GP does not directly own
any shares of Common Stock.
Based on Rule 13d-3 of the Act, Opportunities GP may be
deemed to beneficially own the shares of Common Stock
controlled by Opportunities Portfolio GP, which consists of
the shares of Common Stock directly held by Opportunities Fund.
E. Opportunities Portfolio GP
(a) Amount beneficially owned: 176,376
(b) Percent of class: 0.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
176,376
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 176,376
Opportunities Portfolio GP serves as the general partner of
Opportunities Fund and has the authority to dispose of and vote the shares
of Common Stock directly owned by Opportunities Fund. Opportunities
Portfolio GP does not directly own any shares of Common Stock.
Based on Rule 13d-3 of the Act, Opportunities Portfolio GP
may be deemed to beneficially own the shares of Common Stock
directly held by Opportunities Fund.
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 18 of 20 SEC Filing
Schedule 13G PAGE 18 of 20
CUSIP No. 49803L109
F. VGE
(a) Amount beneficially owned: 562,091
(b) Percent of class: 1.2%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
562,091
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 562,091
VGE has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its general partner, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGE.
G. VGEII
(a) Amount beneficially owned: 32,967
(b) Percent of class: 0.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
32,967
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 32,967
VGEII has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its general partner, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGEII.
H. VGEIII
(a) Amount beneficially owned: 1,053,309
(b) Percent of class: 2.2%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
1,053,309
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 1,053,309
VGEIII has the authority to dispose of and vote the shares
of Common Stock directly owned by it, which power may be
exercised by its investment manager, VGP, and by VGI, an
affiliate of VGP, which provides managerial services to VGEIII.
Viking Global Equities III Ltd. (a Cayman Islands exempted
company) invests substantially all of its assets through VGEIII.
I. VLFM
(a) Amount beneficially owned: 616,489
(b) Percent of class: 1.3%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
616,489
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 616,489
VLFM has the authority to dispose of and vote the
shares of Common Stock directly owned by it, which power may
be exercised by its investment manager, VLFGP, and by VGI,
an affiliate of VLFGP, which provides managerial services
to VLFM. Viking Long Fund LP (a Delaware limited partnership)
and Viking Long Fund III Ltd. (a Cayman Islands exempted
company), through its investment in Viking Long Fund Intermediate
LP (a Cayman Islands limited partnership), invest substantially
all of their assets through VLFM.
J. Opportunities Fund
(a) Amount beneficially owned: 176,376
(b) Percent of class: 0.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
176,376
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 176,376
Opportunities Fund has the authority to dispose of and vote the
shares of Common Stock directly owned by it, which power may
be exercised by its general partner, Opportunities Portfolio GP,
and by VGI, an affiliate of Opportunities Portfolio GP, which provides
managerial services to Opportunities Fund. Viking Global Opportunities LP
(a Delaware limited partnership) and Viking Global Opportunities III LP
(a Cayman Islands exempted limited partnership), through its investment
in Viking Global Opportunities Intermediate LP (a Cayman Islands
exempted limited partnership), invest substantially all of their
assets in Viking Global Opportunities Master LP (a Cayman Islands
exempted limited partnership), which in turn invests through
Opportunities Fund.
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 19 of 20 SEC Filing
Schedule 13G PAGE 19 of 20
CUSIP No. 49803L109
K. O. Andreas Halvorsen, David C. Ott and Daniel S. Sundheim
(a) Amount beneficially owned: 2,441,232
(b) Percent of class: 5.0%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,441,232
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,441,232
Messrs. Halvorsen, Ott and Sundheim, as
Executive Committee Members of Viking Global Partners LLC,
general partner of VGI (“VGPL”), VGP, VLFGP and Opportunities GP,
have shared authority to dispose of and vote the shares of
Common Stock beneficially owned by VGI, VGP, VLFGP and Opportunities GP.
None of Messrs. Halvorsen, Ott and Sundheim directly
owns any shares of Common Stock.
Based on Rule 13d-3 of the Act, each may be deemed to beneficially
own the shares of Common Stock directly held by VGE, VGE II,
VGEIII, VLFM and Opportunities Fund.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the
date hereof the Reporting Persons has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following.[]
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Yes, see Item 4.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))
By signing below each Reporting Person certifies that, to the best
of its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and not held in connection with or as a
participant in any transaction having that purpose or effect.
Follow Kite Pharma Inc. (NASDAQ:KITE)
Follow Kite Pharma Inc. (NASDAQ:KITE)
Page 20 of 20 SEC Filing
Schedule 13G PAGE 20 of 20
CUSIP No. 49803L109
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief,
the undersigned certify that the information set forth in this statement is
true, complete and correct.
DATED: February 29, 2016
/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD., and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP
/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD., and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP
/s/ DANIEL S. SUNDHEIM
By: Daniel S. Sundheim – individually and
as an Executive Committee Member of
VIKING GLOBAL PERFORMANCE LLC, on behalf
of itself and VIKING GLOBAL EQUITIES LP,
VIKING GLOBAL EQUITIES II LP and VGE III PORTFOLIO LTD.,
and as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING LONG FUND GP LLC, on behalf of itself
and VIKING LONG FUND MASTER LTD., and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP